Yu Hwong, MD
Urology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 28
- 8 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
28 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Hwong’s office at (408) 871-5080 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
28 of 28 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| AARP Medicare Advantage from UHC CA-10 (HMO-POS) | UnitedHealthcare | Listed, may be out of date | Jun 10, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$41,231
Medicare paid this office $41,231 for 174 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 83 | $11,093 | $110 |
| New patient visit (45+ min) | 46 | $6,917 | $150 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 14 | $5,202 | $372 |
| Diagnostic exam of bladder and urethra using an endoscope | 13 | $3,061 | $219 |
| Short return visit (20+ min) | 57 | $2,825 | $44 |
See all 9 services
| Return visit (30+ min) | 83 | $11,093 | $110 |
| New patient visit (45+ min) | 46 | $6,917 | $150 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 14 | $5,202 | $372 |
| Diagnostic exam of bladder and urethra using an endoscope | 13 | $3,061 | $219 |
| Short return visit (20+ min) | 57 | $2,825 | $44 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 72 | $1,091 | $14 |
| Urinalysis, manual test | 117 | $542 | $3 |
| Ultrasound measurement of bladder capacity after voiding | 16 | $187 | $12 |
| Manual urinalysis test with examination using microscope, non-automated | 42 | $165 | $4 |
Procedures Medicare counted
| Prostate resection | 1-10 | None |
Who their Medicare patients are
174 Original Medicare patients in 2024. Average age 78 · Women 17% · Also on Medicaid 51% · Health risk score 1.18. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Diabetes 54% · Chronic kidney disease 39% · Coronary heart disease 26% · Cancer 17% · Atrial fibrillation 16% · COPD 15% · Heart failure 11% · Dementia 11% · Stroke 8% · Depression 6%.
The office billed $173,396, Medicare allowed $59,770 and paid $41,231; for 881 services of 35 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 174 | 881 | 78 | 1.18 | $173,396 | $41,231 |
| 2023 | 213 | 851 | 77 | 1.05 | $141,755 | $48,171 |
| 2022 | 247 | 873 | 78 | 1.14 | $162,367 | $56,590 |
| 2021 | 312 | 1,270 | 78 | 1.12 | $201,049 | $70,874 |
| 2020 | 318 | 1,263 | 78 | 1.20 | $218,421 | $70,209 |
| 2019 | 469 | 1,782 | 78 | 1.22 | $299,628 | $95,063 |
| 2018 | 574 | 2,195 | 77 | 1.32 | $433,186 | $132,037 |
| 2017 | 625 | 2,543 | 77 | 1.31 | $532,911 | $176,417 |
| 2016 | 541 | 2,113 | 77 | 1.20 | $415,424 | $133,487 |
| 2015 | 564 | 2,083 | 77 | 1.23 | $401,353 | $130,597 |
| 2014 | 769 | 2,822 | 77 | 1.16 | $571,452 | $196,009 |
| 2013 | 962 | 3,783 | 77 | 1.20 | $806,984 | $272,578 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 8 services
| Short return visit (20+ min) | 154 | $15,154 | $70 |
| New patient visit (45+ min) | 48 | $5,952 | $124 |
| Diagnostic exam of bladder and urethra using an endoscope | 18 | $4,966 | $248 |
| Return visit (30+ min) | 21 | $2,215 | $105 |
| Manual urinalysis test with examination using microscope, non-automated | 164 | $780 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 15 | $164 | $10 |
| Manual urinalysis test with examination using microscope, automated | 22 | $84 | $3 |
| Electronic assessment of bladder emptying | 11 | $68 | $6 |
2022: 11 services
| Short return visit (20+ min) | 186 | $16,886 | $72 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 19 | $7,690 | $384 |
| New patient visit (45+ min) | 49 | $5,147 | $105 |
| Diagnostic exam of bladder and urethra using an endoscope | 16 | $4,661 | $245 |
| Ultrasound scan of pelvic region through rectum | 16 | $2,420 | $151 |
| Return visit (30+ min) | 17 | $1,991 | $117 |
| Short return visit | 15 | $1,153 | $48 |
| Manual urinalysis test with examination using microscope, non-automated | 191 | $831 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 21 | $229 | $10 |
| Electronic assessment of bladder emptying | 19 | $114 | $6 |
| Manual urinalysis test with examination using microscope, automated | 20 | $78 | $3 |
2021: 11 services
| Short return visit (20+ min) | 240 | $23,980 | $73 |
| New patient visit (45+ min) | 72 | $9,737 | $135 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 17 | $6,642 | $391 |
| Diagnostic exam of bladder and urethra using an endoscope | 24 | $6,568 | $243 |
| Ultrasound scan of pelvic region through rectum | 21 | $3,325 | $151 |
| Return visit (30+ min) | 18 | $1,890 | $105 |
| Short return visit | 16 | $1,231 | $49 |
| Manual urinalysis test with examination using microscope, non-automated | 251 | $1,226 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 21 | $191 | $9 |
| Manual urinalysis test with examination using microscope, automated | 31 | $124 | $3 |
| Electronic assessment of bladder emptying | 18 | $109 | $6 |
2020: 10 services
| Short return visit (20+ min) | 249 | $20,480 | $61 |
| Diagnostic exam of bladder and urethra using an endoscope | 36 | $9,370 | $208 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 23 | $8,145 | $339 |
| New patient visit (45+ min) | 63 | $7,786 | $124 |
| Ultrasound scan of pelvic region through rectum | 22 | $3,479 | $151 |
| Manual urinalysis test with examination using microscope, non-automated | 242 | $1,172 | $4 |
| Short return visit | 22 | $1,035 | $37 |
| Ultrasound measurement of bladder capacity after voiding | 29 | $278 | $9 |
| Electronic assessment of bladder emptying | 24 | $132 | $5 |
| Manual urinalysis test with examination using microscope, automated | 29 | $120 | $3 |
2019: 13 services
| Short return visit (20+ min) | 344 | $30,500 | $62 |
| New patient visit (45+ min) | 92 | $13,428 | $146 |
| Diagnostic exam of bladder and urethra using an endoscope | 47 | $10,824 | $183 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 15 | $5,186 | $346 |
| Biopsy of prostate gland | 13 | $3,226 | $248 |
| Return visit (30+ min) | 36 | $2,904 | $81 |
| Ultrasound scan of pelvic region through rectum | 20 | $2,641 | $132 |
| Short return visit | 40 | $1,990 | $39 |
| Manual urinalysis test with examination using microscope, non-automated | 366 | $1,767 | $4 |
| Ultrasonic guidance for needle placement | 13 | $723 | $56 |
| Ultrasound measurement of bladder capacity after voiding | 42 | $487 | $11 |
| Electronic assessment of bladder emptying | 34 | $293 | $9 |
| Manual urinalysis test with examination using microscope, automated | 36 | $190 | $3 |
2018: 15 services
| Short return visit (20+ min) | 398 | $33,940 | $58 |
| New patient visit (45+ min) | 152 | $19,396 | $128 |
| Diagnostic exam of bladder and urethra using an endoscope | 71 | $12,675 | $153 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 15 | $9,873 | $658 |
| Short return visit | 76 | $5,202 | $39 |
| Return visit (30+ min) | 54 | $3,963 | $73 |
| Biopsy of prostate gland | 15 | $3,680 | $245 |
| Ultrasound scan of pelvic region through rectum | 36 | $3,388 | $94 |
| Simple insertion of temporary bladder tube | 17 | $2,837 | $62 |
| Manual urinalysis test with examination using microscope, non-automated | 271 | $1,202 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 66 | $1,049 | $15 |
| Ultrasonic guidance for needle placement | 15 | $818 | $55 |
| Electronic assessment of bladder emptying | 59 | $784 | $13 |
| Automated urinalysis test | 189 | $537 | $3 |
| Manual urinalysis test with examination using microscope, automated | 99 | $507 | $4 |
2017: 19 services
| Short return visit (20+ min) | 404 | $38,310 | $61 |
| New patient visit (45+ min) | 185 | $26,571 | $144 |
| Diagnostic exam of bladder and urethra using an endoscope | 86 | $16,958 | $156 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $14,760 | None |
| Tissue marker, implantable, any type, each | 11 | $7,003 | $241 |
| Biopsy of prostate gland | 22 | $6,057 | $242 |
| Return visit (30+ min) | 65 | $6,010 | $90 |
| Short return visit | 83 | $5,024 | $39 |
| Ultrasound scan of pelvic region through rectum | 44 | $4,835 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $2,332 | $65 |
| Simple insertion of temporary bladder tube | 20 | $2,320 | $61 |
| Ultrasonic guidance for needle placement | 25 | $1,945 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,587 | $122 |
| Automated urinalysis test | 425 | $1,579 | $3 |
| Ultrasound measurement of bladder capacity after voiding | 68 | $1,307 | $19 |
| Placement of device in prostate for radiation therapy | 11 | $1,233 | $112 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $925 | $29 |
| Electronic assessment of bladder emptying | 61 | $879 | $14 |
| Manual urinalysis test with examination using microscope, automated | 140 | $801 | $4 |
2016: 15 services
| Short return visit (20+ min) | 358 | $33,207 | $60 |
| New patient visit (45+ min) | 137 | $18,875 | $138 |
| Diagnostic exam of bladder and urethra using an endoscope | 56 | $12,084 | $189 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $11,347 | None |
| Return visit (30+ min) | 82 | $7,642 | $88 |
| Biopsy of prostate gland | 17 | $3,393 | $200 |
| Short return visit | 63 | $3,247 | $36 |
| Ultrasound scan of pelvic region through rectum | 28 | $2,821 | $91 |
| Automated urinalysis test | 396 | $1,434 | $3 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,429 | $119 |
| Ultrasonic guidance for needle placement | 17 | $1,076 | $54 |
| Ultrasound measurement of bladder capacity after voiding | 48 | $897 | $18 |
| Manual urinalysis test with examination using microscope, automated | 126 | $838 | $4 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $669 | $28 |
| Electronic assessment of bladder emptying | 43 | $613 | $14 |
2015: 11 services
| Short return visit (20+ min) | 415 | $35,947 | $59 |
| Diagnostic exam of bladder and urethra using an endoscope | 69 | $16,215 | $191 |
| New patient visit (45+ min) | 99 | $13,846 | $140 |
| Return visit (30+ min) | 53 | $5,223 | $99 |
| Short return visit | 59 | $2,783 | $39 |
| Ultrasound scan of pelvic region through rectum | 26 | $2,233 | $86 |
| Automated urinalysis test | 425 | $1,656 | $3 |
| Ultrasound measurement of bladder capacity after voiding | 48 | $932 | $19 |
| Manual urinalysis test with examination using microscope, automated | 110 | $667 | $4 |
| Electronic assessment of bladder emptying | 45 | $657 | $14 |
| Smoking and tobacco use intensive counseling, 4-10 minutes | 11 | $167 | $10 |
2014: 18 services
| Short return visit (20+ min) | 611 | $58,443 | $60 |
| Diagnostic exam of bladder and urethra using an endoscope | 83 | $18,843 | $179 |
| New patient visit (45+ min) | 147 | $18,759 | $128 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 12 | $15,110 | None |
| Ultrasound scan of pelvic region through rectum | 42 | $4,347 | $92 |
| Biopsy of prostate gland | 18 | $3,835 | $202 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 11 | $3,264 | $272 |
| Return visit (30+ min) | 28 | $2,783 | $96 |
| Insertion of stent in ureter using an endoscope | 17 | $2,053 | $98 |
| Automated urinalysis test | 527 | $2,052 | $3 |
| Ultrasonic guidance for needle placement | 21 | $1,870 | $72 |
| Complete ultrasound scan behind abdominal cavity | 11 | $1,621 | $135 |
| Ultrasound measurement of bladder capacity after voiding | 52 | $987 | $18 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $958 | $32 |
| Short return visit | 21 | $913 | $42 |
| Electronic assessment of bladder emptying | 45 | $632 | $13 |
| Manual urinalysis test with examination using microscope, automated | 88 | $486 | $4 |
| Manual urinalysis test with examination using microscope, non-automated | 84 | $368 | $4 |
2013: 21 services
| Short return visit (20+ min) | 731 | $69,110 | $57 |
| New patient visit (45+ min) | 260 | $33,225 | $128 |
| Diagnostic exam of bladder and urethra using an endoscope | 113 | $25,522 | $178 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 11 | $11,779 | None |
| Ultrasonic guidance for needle placement | 37 | $9,223 | $214 |
| Biopsy of prostate gland | 35 | $6,879 | $197 |
| Shock wave crushing of kidney stones | 11 | $6,231 | $519 |
| Short return visit | 112 | $5,781 | $39 |
| Ultrasound scan of pelvic region through rectum | 73 | $5,664 | $72 |
| Complete ultrasound of abdomen and pelvis artery and vein blood flow | 23 | $5,234 | $228 |
| Crushing of stone of ureter using an endoscope | 11 | $3,972 | $306 |
| Complete ultrasound scan behind abdominal cavity | 23 | $3,117 | $136 |
| Automated urinalysis test | 681 | $2,761 | $3 |
| Insertion of stent in ureter using an endoscope | 24 | $2,474 | $80 |
| Return visit (30+ min) | 24 | $2,325 | $93 |
| Ultrasound measurement of bladder capacity after voiding | 88 | $1,756 | $19 |
| Electronic assessment of bladder emptying | 89 | $1,258 | $13 |
| New patient visit (30+ min) | 17 | $1,232 | $72 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $823 | $33 |
| Manual urinalysis test with examination using microscope, automated | 99 | $523 | $4 |
| Manual urinalysis test with examination using microscope, non-automated | 66 | $283 | $4 |
Medicaid work
$112 in 2024
Medicaid paid $112 for 53 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| New patient visit (45+ min) | 12 | $101 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 15 | $10 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 26 | $2 |
| 2024 | 53 | 3 | 14 | $112 |
| 2023 | 141 | 3 | 31 | $900 |
| 2022 | 100 | 2 | 18 | $277 |
| 2021 | 289 | 2 | 21 | $720 |
| 2020 | 173 | 2 | 18 | $431 |
| 2019 | 244 | 3 | 26 | $408 |
| 2018 | 283 | 4 | 26 | $969 |
See the largest Medicaid services in earlier years
2023
| New patient visit (45+ min) | 13 | $436 |
| Short return visit (20+ min) | 57 | $415 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 71 | $49 |
2022
| Short return visit (20+ min) | 62 | $257 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 38 | $20 |
2021
| Short return visit (20+ min) | 151 | $680 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 138 | $39 |
2020
| Short return visit (20+ min) | 115 | $426 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 58 | $5 |
2019
| Short return visit (20+ min) | 166 | $400 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 66 | $8 |
| New patient visit (45+ min) | 12 | $0 |
2018
| Short return visit (20+ min) | 182 | $969 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, with microscopy | 74 | $0 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, without microscopy | 13 | $0 |
| New patient visit (45+ min) | 14 | $0 |
Drugs they prescribed that Part D paid
$233,211
Pharmacies billed $233,211 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
739 generic and 166 brand-name prescriptions · $233,211 in drug cost · 55 antibiotic prescriptions to 45 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Elmiron | 80 | $92,466 | $1,156 |
| Myrbetriq | 65 | $43,777 | $673 |
| Tamsulosin | 382 | $5,654 | $15 |
| Finasteride | 98 | $1,996 | $20 |
| Dutasteride | 46 | $1,786 | $39 |
See all 10 drugs
| Elmiron | 80 | $92,466 | $1,156 |
| Myrbetriq | 65 | $43,777 | $673 |
| Tamsulosin | 382 | $5,654 | $15 |
| Finasteride | 98 | $1,996 | $20 |
| Dutasteride | 46 | $1,786 | $39 |
| Heparin | 12 | $287 | $24 |
| Doxazosin Mesylate | 15 | $194 | $13 |
| Bicalutamide | 15 | $134 | $9 |
| Ciprofloxacin | 41 | $128 | $3 |
| Terazosin | 14 | $72 | $5 |
Year by year
| 2024 | 905 | 232 | None | 18% | $233,211 |
| 2023 | 1,140 | 263 | None | None | $636,047 |
| 2022 | 1,373 | 326 | None | None | $993,214 |
| 2021 | 1,564 | 355 | 1% (18) | 24% | $1,393,298 |
| 2020 | 1,759 | 417 | 1% (18) | 20% | $882,388 |
| 2019 | 2,032 | 534 | 1% (16) | None | $583,381 |
| 2018 | 2,484 | 564 | 2% (38) | 14% | $517,729 |
| 2017 | 2,530 | 515 | 2% (51) | None | $297,290 |
| 2016 | 2,381 | 466 | 1% (23) | None | $259,211 |
| 2015 | 2,439 | 462 | 1% (18) | None | $354,803 |
| 2014 | 2,635 | 501 | 1% (33) | None | $360,237 |
| 2013 | 2,996 | 547 | 1% (41) | None | $351,723 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Xtandi | 27 | $397,301 | $14,715 |
| Elmiron | 87 | $118,840 | $1,366 |
| Myrbetriq | 103 | $75,154 | $730 |
| Tamsulosin | 448 | $12,456 | $28 |
| Fesoterodine Fumarate Er | 15 | $4,536 | $302 |
| Dutasteride | 54 | $4,185 | $78 |
| Finasteride | 128 | $3,114 | $24 |
| Oxybutynin Chloride Er | 24 | $1,423 | $59 |
| Bicalutamide | 24 | $1,057 | $44 |
| Alfuzosin Hcl Er | 11 | $539 | $49 |
| Terazosin | 13 | $507 | $39 |
| Ciprofloxacin | 46 | $354 | $8 |
| Heparin | 13 | $276 | $21 |
| Sildenafil Citrate | 16 | $167 | $10 |
| Zolpidem | 11 | $131 | $12 |
2022: 12 drugs
| Xtandi | 54 | $728,964 | $13,499 |
| Elmiron | 106 | $126,930 | $1,197 |
| Myrbetriq | 114 | $80,945 | $710 |
| Tamsulosin | 561 | $11,676 | $21 |
| Toviaz | 15 | $11,102 | $740 |
| Dutasteride | 56 | $4,904 | $88 |
| Finasteride | 161 | $4,524 | $28 |
| Bicalutamide | 52 | $2,453 | $47 |
| Oxybutynin Chloride Er | 36 | $1,921 | $53 |
| Tolterodine Tartrate Er | 14 | $1,716 | $123 |
| Terazosin | 23 | $582 | $25 |
| Ciprofloxacin | 57 | $370 | $6 |
2021: 16 drugs
| Xtandi | 88 | $1,096,783 | $12,463 |
| Elmiron | 107 | $112,414 | $1,051 |
| Myrbetriq | 127 | $86,280 | $679 |
| Toviaz | 27 | $18,592 | $689 |
| Tamsulosin | 606 | $11,418 | $19 |
| Dutasteride | 81 | $6,816 | $84 |
| Finasteride | 187 | $4,684 | $25 |
| Tolterodine Tartrate Er | 13 | $2,331 | $179 |
| Bicalutamide | 40 | $2,319 | $58 |
| Oxybutynin Chloride Er | 31 | $1,454 | $47 |
| Doxazosin Mesylate | 22 | $694 | $32 |
| Ciprofloxacin | 72 | $380 | $5 |
| Terazosin | 13 | $264 | $20 |
| Cephalexin | 14 | $150 | $11 |
| Sildenafil Citrate | 11 | $98 | $9 |
| Hydrocodone-Acetaminophen | 18 | $75 | $4 |
2020: 16 drugs
| Xtandi | 52 | $629,368 | $12,103 |
| Elmiron | 128 | $135,051 | $1,055 |
| Myrbetriq | 107 | $53,368 | $499 |
| Toviaz | 39 | $17,674 | $453 |
| Tamsulosin | 707 | $10,525 | $15 |
| Dutasteride | 85 | $5,843 | $69 |
| Finasteride | 254 | $4,383 | $17 |
| Tolterodine Tartrate Er | 17 | $3,793 | $223 |
| Oxybutynin Chloride Er | 47 | $2,565 | $55 |
| Bicalutamide | 47 | $2,428 | $52 |
| Doxazosin Mesylate | 32 | $1,252 | $39 |
| Ciprofloxacin | 98 | $539 | $6 |
| Terazosin | 17 | $271 | $16 |
| Sulfamethoxazole-Trimethoprim | 13 | $96 | $7 |
| Hydrocodone-Acetaminophen | 18 | $82 | $5 |
| Sildenafil Citrate | 13 | $77 | $6 |
2019: 19 drugs
| Xtandi | 30 | $349,405 | $11,647 |
| Elmiron | 139 | $141,927 | $1,021 |
| Myrbetriq | 37 | $19,252 | $520 |
| Tamsulosin | 758 | $13,423 | $18 |
| Vesicare | 14 | $11,906 | $850 |
| Tolterodine Tartrate Er | 33 | $7,220 | $219 |
| Finasteride | 327 | $6,872 | $21 |
| Toviaz | 17 | $5,943 | $350 |
| Dutasteride | 78 | $3,987 | $51 |
| Bicalutamide | 111 | $3,727 | $34 |
| Oxybutynin Chloride Er | 55 | $2,619 | $48 |
| Doxazosin Mesylate | 39 | $1,804 | $46 |
| Ciprofloxacin | 215 | $1,081 | $5 |
| Nitrofurantoin Mono-Macro | 15 | $616 | $41 |
| Alfuzosin Hcl Er | 12 | $453 | $38 |
| Terazosin | 12 | $330 | $27 |
| Zolpidem | 12 | $206 | $17 |
| Sulfamethoxazole-Trimethoprim | 14 | $127 | $9 |
| Hydrocodone-Acetaminophen | 16 | $91 | $6 |
2018: 22 drugs
| Xtandi | 16 | $174,966 | $10,935 |
| Elmiron | 150 | $159,444 | $1,063 |
| Myrbetriq | 68 | $43,386 | $638 |
| Vesicare | 51 | $31,500 | $618 |
| Tamsulosin | 875 | $19,653 | $22 |
| Tolterodine Tartrate Er | 63 | $9,653 | $153 |
| Finasteride | 374 | $7,630 | $20 |
| Bicalutamide | 180 | $5,885 | $33 |
| Oxybutynin Chloride Er | 107 | $5,573 | $52 |
| Dutasteride | 116 | $5,231 | $45 |
| Rapaflo | 14 | $4,398 | $314 |
| Doxazosin Mesylate | 60 | $2,191 | $37 |
| Ciprofloxacin | 177 | $1,070 | $6 |
| Alfuzosin Hcl Er | 13 | $558 | $43 |
| Nitrofurantoin Mono-Macro | 16 | $544 | $34 |
| Trospium Chloride | 11 | $447 | $41 |
| Terazosin | 18 | $252 | $14 |
| Allopurinol | 16 | $185 | $12 |
| Sulfamethoxazole-Trimethoprim | 26 | $149 | $6 |
| Acetaminophen-Codeine | 23 | $102 | $4 |
| Zolpidem | 14 | $98 | $7 |
| Hydrocodone-Acetaminophen | 14 | $74 | $5 |
2017: 20 drugs
| Elmiron | 82 | $89,412 | $1,090 |
| Vesicare | 74 | $36,849 | $498 |
| Myrbetriq | 66 | $32,328 | $490 |
| Tamsulosin | 820 | $19,894 | $24 |
| Bicalutamide | 225 | $9,323 | $41 |
| Tolterodine Tartrate Er | 49 | $7,996 | $163 |
| Dutasteride | 152 | $7,724 | $51 |
| Finasteride | 424 | $7,629 | $18 |
| Rapaflo | 20 | $6,324 | $316 |
| Oxybutynin Chloride Er | 108 | $5,545 | $51 |
| Doxazosin Mesylate | 79 | $2,432 | $31 |
| Ciprofloxacin | 140 | $665 | $5 |
| Nitrofurantoin Mono-Macro | 13 | $557 | $43 |
| Alfuzosin Hcl Er | 15 | $528 | $35 |
| Terazosin | 38 | $339 | $9 |
| Hydrocodone-Acetaminophen | 48 | $261 | $5 |
| Allopurinol | 16 | $231 | $14 |
| Sulfamethoxazole-Trimethoprim | 36 | $172 | $5 |
| Cephalexin | 23 | $168 | $7 |
| Zolpidem | 12 | $53 | $4 |
2016: 21 drugs
| Elmiron | 97 | $93,158 | $960 |
| Vesicare | 69 | $27,015 | $392 |
| Myrbetriq | 59 | $25,685 | $435 |
| Tamsulosin | 867 | $23,828 | $27 |
| Dutasteride | 177 | $9,805 | $55 |
| Bicalutamide | 177 | $6,768 | $38 |
| Rapaflo | 32 | $6,739 | $211 |
| Finasteride | 334 | $5,392 | $16 |
| Avodart | 17 | $4,681 | $275 |
| Oxybutynin Chloride Er | 61 | $3,834 | $63 |
| Tolterodine Tartrate Er | 18 | $3,242 | $180 |
| Doxazosin Mesylate | 86 | $3,042 | $35 |
| Nitrofurantoin Mono-Macro | 20 | $1,153 | $58 |
| Ciprofloxacin | 153 | $1,056 | $7 |
| Alfuzosin Hcl Er | 11 | $402 | $37 |
| Terazosin | 29 | $309 | $11 |
| Hydrocodone-Acetaminophen | 22 | $209 | $10 |
| Sulfamethoxazole-Trimethoprim | 33 | $161 | $5 |
| Amitriptyline | 15 | $78 | $5 |
| Cephalexin | 14 | $77 | $6 |
| Zolpidem | 12 | $60 | $5 |
2015: 20 drugs
| Elmiron | 112 | $100,220 | $895 |
| Avodart | 249 | $65,951 | $265 |
| Tamsulosin | 919 | $30,816 | $34 |
| Vesicare | 86 | $28,845 | $335 |
| Myrbetriq | 59 | $22,091 | $374 |
| Rapaflo | 47 | $13,336 | $284 |
| Bicalutamide | 160 | $6,698 | $42 |
| Dutasteride | 26 | $5,271 | $203 |
| Jalyn | 12 | $5,049 | $421 |
| Finasteride | 294 | $4,899 | $17 |
| Doxazosin Mesylate | 98 | $3,784 | $39 |
| Tolterodine Tartrate Er | 11 | $2,999 | $273 |
| Oxybutynin Chloride Er | 34 | $2,120 | $62 |
| Ciprofloxacin | 125 | $752 | $6 |
| Nitrofurantoin Mono-Macro | 11 | $488 | $44 |
| Alfuzosin Hcl Er | 21 | $440 | $21 |
| Terazosin | 49 | $386 | $8 |
| Hydrocodone-Acetaminophen | 13 | $193 | $15 |
| Cephalexin | 14 | $101 | $7 |
| Sulfamethoxazole-Trimethoprim | 13 | $77 | $6 |
2014: 21 drugs
| Elmiron | 98 | $87,208 | $890 |
| Avodart | 323 | $75,406 | $233 |
| Vesicare | 114 | $32,110 | $282 |
| Tamsulosin | 927 | $22,876 | $25 |
| Myrbetriq | 71 | $17,597 | $248 |
| Rapaflo | 48 | $13,294 | $277 |
| Jalyn | 29 | $8,248 | $284 |
| Bicalutamide | 146 | $6,786 | $46 |
| Finasteride | 265 | $5,250 | $20 |
| Oxybutynin Chloride Er | 40 | $4,303 | $108 |
| Doxazosin Mesylate | 117 | $4,143 | $35 |
| Toviaz | 12 | $2,433 | $203 |
| Enablex | 11 | $2,253 | $205 |
| Alfuzosin Hcl Er | 27 | $1,940 | $72 |
| Nitrofurantoin Mono-Macro | 18 | $937 | $52 |
| Ciprofloxacin | 143 | $772 | $5 |
| Oxybutynin Chloride | 18 | $700 | $39 |
| Terazosin | 52 | $478 | $9 |
| Hydrocodone-Acetaminophen | 27 | $397 | $15 |
| Cephalexin | 23 | $205 | $9 |
| Sulfamethoxazole-Trimethoprim | 21 | $103 | $5 |
2013: 23 drugs
| Avodart | 453 | $87,982 | $194 |
| Elmiron | 110 | $80,411 | $731 |
| Vesicare | 173 | $47,401 | $274 |
| Nilandron | 11 | $28,344 | $2,577 |
| Tamsulosin | 968 | $21,328 | $22 |
| Bicalutamide | 198 | $12,154 | $61 |
| Rapaflo | 42 | $11,429 | $272 |
| Jalyn | 37 | $9,081 | $245 |
| Finasteride | 256 | $8,614 | $34 |
| Oxybutynin Chloride Er | 70 | $8,199 | $117 |
| Enablex | 24 | $4,373 | $182 |
| Detrol La | 11 | $3,922 | $357 |
| Toviaz | 12 | $3,021 | $252 |
| Doxazosin Mesylate | 127 | $2,524 | $20 |
| Alfuzosin | 31 | $1,541 | $50 |
| Nitrofurantoin Mono-Macro | 24 | $1,454 | $61 |
| Ciprofloxacin | 181 | $1,077 | $6 |
| Terazosin | 52 | $580 | $11 |
| Oxybutynin Chloride | 16 | $316 | $20 |
| Hydrocodone-Acetaminophen | 40 | $289 | $7 |
| Cephalexin | 18 | $164 | $9 |
| Amitriptyline | 25 | $128 | $5 |
| Sulfamethoxazole-Trimethoprim | 16 | $117 | $7 |
Money from drug and device companies
$182 in 2025
| 2025 | 4 | 7 | None | $182 |
| 2024 | 5 | 7 | None | $235 |
| 2023 | 5 | 17 | None | $525 |
| 2022 | 4 | 11 | None | $236 |
| 2021 | 4 | 15 | None | $423 |
| 2020 | 4 | 13 | None | $275 |
| 2019 | 7 | 49 | None | $917 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sumitomo Pharma America | Gemtesa | $99 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | None | $33 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $28 | 1 payment
|
| Accord Healthcare | Camcevi | $22 | 1 payment
|
See all 7 published payments
| Sumitomo Pharma America | Meals · 2025-07-28 | Gemtesa | $17 |
| Accord Healthcare | Meals · 2025-07-10 | Camcevi | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-17 | None | $33 |
| Sumitomo Pharma America | Meals · 2025-06-11 | Gemtesa | $44 |
| Sumitomo Pharma America | Meals · 2025-06-03 | Gemtesa | $14 |
| Progenics Pharmaceuticals | Meals · 2025-04-09 | Pylarify | $28 |
| Sumitomo Pharma America | Meals · 2025-02-06 | Gemtesa | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $235
| Sumitomo Pharma America | Gemtesa | $108 | 3 payments
|
| Astellas Pharma US | Xtandi | $35 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $33 | 1 payment
|
| Janssen Biotech | Erleada | $32 | 1 payment
|
| Pfizer | Xtandi | $27 | 1 payment
|
2023: $525
| Sumitomo Pharma America | Gemtesa | $228 | 7 payments
|
| Janssen Biotech | Erleada | $126 | 4 payments
|
| Astellas Pharma US | Xtandi | $96 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Nubeqa | $43 | 2 payments
|
| Amgen | Xgeva | $32 | 1 payment
|
2022: $236
| Urovant Sciences | Gemtesa | $122 | 6 payments
|
| Astellas Pharma US | Xtandi | $48 | 2 payments
|
| Janssen Biotech | Erleada | $38 | 2 payments
|
| Progenics Pharmaceuticals | Pylarify | $29 | 1 payment
|
2021: $423
| Urovant Sciences | Gemtesa | $177 | 7 payments
|
| Janssen Biotech | Erleada | $106 | 2 payments
|
| Astellas Pharma US | Xtandi | $97 | 4 payments
|
| Boston Scientific | General Bph | $43 | 2 payments
|
2020: $275
| Astellas Pharma US | Myrbetriq | $160 | 7 payments
|
| Pfizer | Xtandi | $66 | 4 payments
|
| Janssen Biotech | Erleada | $25 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $25 | 1 payment
|
2019: $917
| Janssen Biotech | Erleada | $252 | 13 payments
|
| Pfizer | Xtandi | $243 | 17 payments
|
| Astellas Pharma US | Xtandi | $232 | 10 payments
|
| Ferring Pharmaceuticals | Nocdurna | $79 | 3 payments
|
| Boston Scientific | General Bph | $67 | 4 payments
|
| Dendreon Pharmaceuticals | Provenge | $31 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Xofigo | $14 | 1 payment
|
Professional record
- NPI
- 1306899208
- Licence
- CA G047398
- Trained
- Loyola University of Chicago, Stritch School of Medicine, 1979
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X); Federal specialty code 174400000X (174400000X)
- Mailing address
- 200 Jose Figueres Ave, Ste 425, San Jose, CA, 95116
- NPI first listed
- 2006-05-19
- NPI last updated
- 2025-01-08
- NPI record certified
- 2025-01-08
This is when the NPI record was last certified, not a medical board exam.